Develops and manufactures generic and specialty pharmaceuticals. Offers a wide range of dosage forms including oral solids, injectables, and topicals. Now — the numbers.
This is an established company with proven profits.
Average growth of 10% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $2.4B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 10% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The company’s market value is 75 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 24/100.
Costs swallow the gains that sales growth brings in.
On our five-subject report card, AMRX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AMRX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.